


# PHARMACEUTICAL 2018

#### Monopar Therapeutics

# Monopar Therapeutics Rank 329 of 349



# RealRate

### PHARMACEUTICAL 2018



# Monopar Therapeutics Rank 329 of 349

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 282% points. The greatest weakness of Monopar Therapeutics is the variable Other Expenses, reducing the Economic Capital Ratio by 1,022% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,106%, being 828% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	9,131
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	312
Liabilities, Non-Current	0
Other Assets	800
Other Compr. Net Income	0
Other Expenses	14,502
Other Liabilities	0
Other Net Income	48
Property and Equipment	0
Research and Development	935
Revenues	0
Selling, General and Administrative Expense	1,166

Output Variable	Value in 1000 USD
Assets	9,931
Liabilities	312
Expenses	16,603
Stockholders Equity	9,619
Net Income	-16,555
Comprehensive Net Income	-16,555
Economic Capital Ratio	-1,106%